Lyra Therapeutics Inc Stock News
$0.10
9.82%
yesterday
Nasdaq,
May 20, 10:15 pm CET
Lyra Therapeutics Inc Stock News
Neutral
GlobeNewsWire
●
14 days ago
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for ...
Neutral
GlobeNewsWire
●
15 days ago
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – – Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 –
Neutral
GlobeNewsWire
●
2 months ago
WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate upd...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
